PlainRecalls
LowClass IIITerminated

FDA Drug recall · Reported October 17, 2018

Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise FL 33323 UPC 369097128159, NDC 69097-128-15

Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.

Recall #
D-0012-2019
Affected scope
2880 bottles
Initiated
October 3, 2018
Verify with FDA Drug →
View my saved recalls

InvaGen Pharmaceuticals, Inc. recalled Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipl… - a low-severity action.

Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipl… was recalled by InvaGen Pharmaceuticals, Inc. in October 17, 2018. Reason: Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long te…. Check the official notice for the remedy. Verify recall #D-0012-2019 with the FDA Drug before acting.

The recall

InvaGen Pharmaceuticals, Inc. issued this low-severity FDA Drug recall-Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long te….

Low
severity level
Class III
classification
October 17, 2018
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0012-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,472 drugs & medications recalls on record

05001,0001,5002,000 2006201220152018202120242026 448
Severity1906864652High severity (most serious)Moderate severityLow severity
Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise FL 33323 UPC 369097128159, NDC 69097-128-15

Reason for recall

Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Low (Class III)
Status Terminated
Recall number D-0012-2019
Date reported October 17, 2018
Date initiated October 3, 2018
Recalling firm InvaGen Pharmaceuticals, Inc.
Firm location Hauppauge, NY
Affected scope 2880 bottles
Distribution Nationwide with the United States

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0012-2019) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise FL 33323 UPC 369097128159, NDC 69097-128-15. Recalled by InvaGen Pharmaceuticals, Inc.. Units affected: 2880 bottles.
Why was this product recalled?
Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 17, 2018. Severity: Low. Recall number: D-0012-2019.
Where was the recalled product distributed?
Distribution: Nationwide with the United States.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported October 17, 2018. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026